Chemokine MIP-2/CXCL2, acting on CXCR2, induces motor neuron death in primary cultures
Abstract
OBJECTIVES: Chemokines are implicated in many diseases of the central nervous system (CNS). Although their primary role is to induce inflammation through the recruitment of leukocytes by their chemotactic activity, they may also have direct effects on neuronal cells. We evaluated the expression of CXCR1 and CXCR2 and investigated the effect of CXCR2 activation by the agonist MIP-2 (CXCL2) on primary cultured motor neurons. To specifically assess the role of CXCR2 in the neurotoxicity induced by MIP-2, we used the CXCR1/2 inhibitor reparixin and studied the effect of the chemokine on motor neuron cultures from CXCR2-deficient mice. METHODS: Primary motor neurons prepared from rat or mouse embryos were treated with MIP-2 and reparixin. Motor neuron viability and receptor expression were assessed by immunocytochemical techniques. RESULTS: Rat primary motor neurons expressed CXCR2 receptors and recombinant rat MIP-2 induced dose-dependent neurotoxicity. This neurotoxicity was counteracted by reparixin, a specific CXCR1/2 inhibitor, and was not observed in motor neurons from CXCR2-deficient mice. CONCLUSIONS: CXCR2 activation might directly contribute to motor neuron degeneration. Thus, chemokines acting on CXCR2, including IL-8, may have direct pathogenic effects in CNS diseases, independent of the induction of leukocyte migration.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Chemokines like CXCL2 work via the chemokine receptor CXCR2 in neuronal cells, where they are involved in the pathophysiology of Alzheimer's disease.
“Moreover, chemokines like CXCL2 work via the chemokine receptor (CXCR2) in neuronal cells, where they are involved in the pathophysiology of AD [148].”
From Beneficial Effects of Spirulina Consumption on Brain Health (2022) · cites this paper as [148]
Cites
Cartier, L., Hartley, O., Dubois‐Dauphin, M., & Krause, K. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.07.021 · Cited by 507 · see citing works
Expression of chemokine receptors by subsets of neurons in the central nervous system
Horuk, R., Martin, A. W., Wang, Z., Schweitzer, L., Gerassimides, A., Guo, H.-D., Lu, Z., Hesselgesser, J., Perez, H. D., Kim, J., et al. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.6.2882 · Cited by 385 · see citing works
Traynor, B. J., Codd, M., Corr, B., Forde, C., Frost, E., & Hardiman, O. M. (2000) · PubMed · doi:10.1001/archneur.57.8.1171 · Cited by 378 · see citing works
Bertini, R., Allegretti, M., Bizzarri, C., Moriconi, A., Locati, M., Zampella, G., Cervellera, M. N., Cioccio, V. D., Cesta, M. C., Galliera, E., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402090101 · Cited by 334 · see citing works
A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis
Barbeito, L., Pehar, M., Cassina, P., Vargas, M. R., Peluffo, H., Viera, L., Estévez, Á. G., & Beckman, J. S. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.05.003 · Cited by 331 · see citing works
Araujo, D. M., & Cotman, C. W. (1993) · Brain Research · doi:10.1016/0006-8993(93)90400-h · Cited by 237 · see citing works
Microglia as potential contributors to motor neuron injury in amyotrophic lateral sclerosis
Sargsyan, S. A., Monk, P. N., & Shaw, P. J. (2005) · Glia · doi:10.1002/glia.20210 · Cited by 201 · see citing works
Poloni, M., Facchetti, D., Mai, R., Micheli, A., Agnoletti, L., Francolini, G., Mora, G., Camana, C., Mazzini, L., & Bachetti, T. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01177-0 · Cited by 197 · see citing works
CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis
Omari, K. M., John, G. R., Sealfon, S. C., & Raine, C. S. (2005) · Brain · doi:10.1093/brain/awh479 · Cited by 196 · see citing works
Excitotoxic and oxidative cross-talk between motor neurons and glia in ALS pathogenesis
Rao, S. D., & Weiss, J. H. (2003) · Trends in Neurosciences · doi:10.1016/j.tins.2003.11.001 · Cited by 168 · see citing works
Sekizawa, T., Openshaw, H., Ohbo, K., Sugamura, K., Itoyama, Y., & Niland, J. C. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(97)00228-1 · Cited by 150 · see citing works
Elevated IL-6 and TNF-α levels in patients with ALS: Inflammation or hypoxia?
Moreau, C., Devos, D., Danel-Brunaud, V., Defebvre, L., Perez, T., Destée, A., Tonnel, A., Lassalle, P., & Just, N. (2005) · Neurology · doi:10.1212/01.wnl.0000188907.97339.76 · Cited by 146 · see citing works
Role for CXCR2 and CXCL1 on glia in multiple sclerosis
Omari, K. M., John, G. R., Lango, R., & Raine, C. S. (2005) · Glia · doi:10.1002/glia.20246 · Cited by 137 · see citing works
Survival of Patients with Amyotrophic Lateral Sclerosis in a Population-Based Registry
Millul, A., Beghi, E., Logroscino, G., Micheli, A., Vitelli, E., & Zardi, A. (2005) · Neuroepidemiology · doi:10.1159/000086353 · Cited by 134 · see citing works
Prognosis of amyotrophic lateral sclerosis and the effect of referral selection
Lee, J. R.-J., Annegers, J. F., & Appel, S. H. (1995) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00154-t · Cited by 128 · see citing works
Bruno, V., Copani, A., Besong, G. E., Scoto, G. M., & Nicoletti, F. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00367-8 · Cited by 118 · see citing works
Production of monocyte chemoattractant protein‐1 in amyotrophic lateral sclerosis
Baron, P., Bussini, S., Cardin, V., Corbo, M., Conti, G. M., Galimberti, D., Scarpini, E. A., Bresolin, N., Wharton, S. B., Shaw, P. J., et al. (2005) · Muscle & Nerve · doi:10.1002/mus.20376 · Cited by 111 · see citing works
Xia, M., & Hyman, B. T. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00463-5 · Cited by 105 · see citing works
Kalehua, A. N., Nagel, J. E., Whelchel, L. M., Gides, J. J., Pyle, R. S., Smith, R., Kusiak, J. W., & Taub, D. D. (2004) · Experimental Cell Research · doi:10.1016/j.yexcr.2004.02.031 · Cited by 102 · see citing works
Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia
GARAU, A., Bertini, R., Colotta, F., Casilli, F., Bigini, P., Cagnotto, A., Mennini, T., Ghezzi, P., & VILLA, P. (2005) · Cytokine · doi:10.1016/j.cyto.2004.12.014 · Cited by 93 · see citing works
Villa, P., Triulzi, S., Cavalieri, B., Bitondo, R. D., Bertini, R., Barbera, S., Bigini, P., Mennini, T., Gelosa, P., Tremoli, E., et al. (2007) · Molecular Medicine · doi:10.2119/2007-00008.villa · Cited by 91 · see citing works
Survival Prediction in Sporadic Amyotrophic Lateral Sclerosis
Preux, P., Couratier, P., Boutros-Toni, F., Salle, J., Tabaraud, F., Bernet-Bernady, P., Vallat, J. M., & Dumas, M. (1996) · Neuroepidemiology · doi:10.1159/000109902 · Cited by 74 · see citing works
Thirumangalakudi, L., Yin, L., Rao, H. V., & Grammas, P. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11307 · Cited by 73 · see citing works
Limatola, C., Ciotti, M. T., Mercanti, D., Vacca, F., Ragozzino, D., Giovannelli, A., Santoni, A., Eusebi, F., & Miledi, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.090105997 · Cited by 65 · see citing works
Gorio, A., Madaschi, L., Zadra, G., Marfia, G., Cavalieri, B., Bertini, R., & Giulio, A. M. D. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.123679 · Cited by 59 · see citing works
Gallo, P., Sivieri, S., Rinaldi, L., Yan, X.-B., Lolli, F., Rossi, A. D., & Tavolato, B. F. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90093-0 · Cited by 51 · see citing works
Limatola, C., Ciotti, M. T., Mercanti, D., Santoni, A., & Eusebi, F. (2002) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(01)00472-6 · Cited by 40 · see citing works
Amyotrophic Lateral Sclerosis: Interleukin-6 Levels in Cerebrospinal Fluid
Krieger, C., Perry, T. L., & Ziltener, H. J. (1992) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100041998 · Cited by 26 · see citing works
Comoletti, D., Muzio, V., Capobianco, A., Ravizza, T., & Mennini, T. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00607-4 · Cited by 23 · see citing works
Ford, L. S., & Rowe, D. B. (2004) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/14660820410019125 · Cited by 14 · see citing works
Wilms, H., Rosenstiel, P. C., Sievers, J., Deuschl, G., & Lucius, R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02237-6 · Cited by 9 · see citing works
Stuerenburg, H. J., Jung, R., & Schoser, B. G. H. (1999) · Archives of Gerontology and Geriatrics · doi:10.1016/s0167-4943(99)00018-7 · Cited by 7 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Ramesh, G., MacLean, A. G., & Philipp, M. T. (2013) · Mediators of Inflammation · doi:10.1155/2013/480739 · Cited by 639 · see citing works
“CXCR1, the receptor forMIP-2 (CXCL2) and CXCR2, has also been implicated in contributing directly to motor-neuron degeneration [35].”
BackgroundRole of Chemokines in CNS Health and Pathology: A Focus on the CCL2/CCR2 and CXCL8/CXCR2 Networks
Semple, B. D., Kossmann, T., & Morganti-Kossmann, M. C. (2009) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.240 · Cited by 457 · see citing works
Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin
Brines, M. L., Patel, N. S. A., Villa, P., Brines, C. M., Mennini, T., Paola, M. D., Erbayraktar, Z., Erbayraktar, S., Sepodes, B. M. N., Thiemermann, C., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805594105 · Cited by 320 · see citing works
“The UT-7 EPO hematopoietic assay (10, 17), motoneuron excitotoxicity study (15, 43), 0 2 4 6 8 10 0 3 6 9 12 PBS”
Skelly, D., Hennessy, E., Dansereau, M., & Cunningham, C. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069123 · Cited by 278 · see citing works
CXCR2 antagonists for the treatment of pulmonary disease
Chapman, R. W., Phillips, J. E., Hipkin, R. W., Curran, A. K., Lundell, D., & Fine, J. S. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.005 · Cited by 214 · see citing works
Microglia and CNS Interleukin-1: Beyond Immunological Concepts
Liu, X., & Quan, N. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00008 · Cited by 214 · see citing works
“CXCL4 (59), was the first to be identified in this regard; more recent studies also found CCL11 (60), CXCL2 (61) can exert neurotoxic effects on cultured neurons.”
P2X7 receptor activation induces CXCL2 production in microglia through NFAT and PKC/MAPK pathways
Shiratori, M., Tozaki‐Saitoh, H., Yoshitake, M., Tsuda, M., & Inoue, K. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06809.x · Cited by 153 · see citing works
“…reports indicate that CXCR2 is involved in Alzheimer’s disease (Bakshi et al. 2009), ischemia (Popivanova et al. 2003), traumatic injury (Valles et al. 2006), multiple sclerosis (Kerstetter et al. 2009), neuronal death (De Paola et al. 2007) and opioid receptor function (Parenty et al. 2008).”
Can Infections Cause Alzheimer's Disease?
Mawanda, F., & Wallace, R. B. (2013) · Epidemiologic Reviews · doi:10.1093/epirev/mxs007 · Cited by 151 · see citing works
Neuregulin-1/ErbB network: An emerging modulator of nervous system injury and repair
Kataria, H., Alizadeh, A., & Karimi‐Abdolrezaee, S. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101643 · Cited by 138 · see citing works
The sciatic nerve injury model in pre-clinical research
Geuna, S. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.01.021 · Cited by 138 · see citing works
“…primary neuronal and glial cell lines (Moreno-Flores et al., 2006, Hara et al., 2008; Sak and Illes, 2005; Shastry et al., 2001; Trotter, 1993, De Paola et al., 2007, Scanlin et al., 2008) have been proposed for replacing in vivo pre-clinical models, their potential is still limited and, yet,…”
BackgroundLeung, K. W., Barnstable, C. J., & Tombran‐Tink, J. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2008.12.001 · Cited by 110 · see citing works
Beneficial Effects of Spirulina Consumption on Brain Health
Trotta, T., Porro, C., Cianciulli, A., & Panaro, M. A. (2022) · Nutrients · doi:10.3390/nu14030676 · Cited by 98 · see citing works
CXCR1/2 Inhibition Blocks and Reverses Type 1 Diabetes in Mice
Citro, A., Valle, A., Cantarelli, E., Mercalli, A., Pellegrini, S., Liberati, D., Daffonchio, L., Kastsiuchenka, O., Ruffini, P. A., Battaglia, M., et al. (2014) · Diabetes · doi:10.2337/db14-0443 · Cited by 90 · see citing works
“Notably, DF1726A, a compound structurally related to reparixin but not active on CXCR1/2 (34), did not prevent diabetes development when administered in the same experimental conditions (Supplementary Fig.”
BackgroundTos, P., Ronchi, G., Papalia, I., Sallen, V., Legagneux, J., Geuna, S., & Giacobini-Robecchi, M. G. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)87004-9 · Cited by 85 · see citing works
Skelly, D. T., Hennessy, E., Dansereau, M.-A., & Cunningham, C. (2013) · PLoS ONE · doi:10.1371/annotation/90c76048-2edd-4315-8404-4d9d8cbd411e · Cited by 77 · see citing works
Zhang, T., Zhou, J., Man, G. C. W., Leung, K. T., Liang, B., Xiao, B., Ma, X., Huang, S., Huang, H., Hegde, V. L., et al. (2018) · European Journal of Immunology · doi:10.1002/eji.201747417 · Cited by 68 · see citing works
Neuregulin-1 elicits a regulatory immune response following traumatic spinal cord injury
Alizadeh, A., Santhosh, K. T., Kataria, H., GOUNNI, A. S., & Karimi‐Abdolrezaee, S. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1093-9 · Cited by 66 · see citing works
“CXCL2 is known to induce neuronal injury in motoneuron cultures [71] supportive of a neuroprotective role for Nrg-1 in CNS injury.”
Clayton, A. M., Shao, Q., Paauw, N. D., Giambrone, A. B., Granger, J. P., & Warrington, J. P. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.03.028 · Cited by 61 · see citing works
“While there are no studies reporting MIP-2 levels in preeclampsia patients, there have been reports of neurotoxic effects on primary neuron cultures (De Paola et al., 2007).”
Barreto, G. E., White, R., Xu, L., Palm, C. J., & Giffard, R. G. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2012.08.015 · Cited by 59 · see citing works
Dasari, R., Bonsack, F., & Sukumari‐Ramesh, S. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104923 · Cited by 43 · see citing works
Potential neurotoxic activity of diverse molecules released by astrocytes
Murray, T. E., Richards, C. M., Robert-Gostlin, V. N., Bernath, A. K., Lindhout, I. A., & Klegeris, A. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.08.015 · Cited by 40 · see citing works
A Potential Contribution of Chemokine Network Dysfunction to the Depressive Disorders
lusarczyk, J., Trojan, E., Chwastek, J., Głombik, K., & Basta‐Kaim, A. (2016) · Current Neuropharmacology · doi:10.2174/1570159x14666160219131357 · Cited by 37 · see citing works
“In line with this suggestion, CXCR2 knockout mice (CXCR2-/-) showed the reduced tissue damage and milder neuronal loss in comparison to wild-type mice [112].”
Merabova, N., Kaminski, R., Krynska, B., Amini, S., Khalili, K., & Darbinyan, A. (2011) · Journal of Cellular Physiology · doi:10.1002/jcp.23065 · Cited by 35 · see citing works
Nutraceutical and therapeutic potential of Phycocyanobilin for treating Alzheimer’s disease
Piniella‐Matamoros, B., Marín‐Prida, J., & Pentón‐Rol, G. (2021) · Journal of Biosciences · doi:10.1007/s12038-021-00161-7 · Cited by 34 · see citing works
Pandey, G. N., Rizavi, H. S., Bhaumik, R., & Zhang, H. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.01.033 · Cited by 34 · see citing works
Raman, D., Milatovic, S., Milatović, D., Splittgerber, R. C., Fan, G.-H., & Richmond, A. J. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.06.006 · Cited by 31 · see citing works
“Given the conflicting reports as to whether CXCR2 activation is linked to neuroprotection or neurotoxicity (De Paola et al., 2007; Hosking et al., 2010; Liu et al., 2010), the present study was conducted to test the hypothesis that chemokines MIP-2 and CXCL12 are neuroprotective against Aβ-induced…”
BackgroundMorello, G., Spampinato, A. G., Conforti, F. L., D’Agata, V., & Cavallaro, S. (2017) · Journal of Molecular Neuroscience · doi:10.1007/s12031-017-0898-9 · Cited by 25 · see citing works
“…blocking CXCR2 (e.g., reparixin, navarixin, elubrixin, SB332235) are currently tested in preclinical or clinical trials as anti-inflammatory agents and, among these, reparixin has shown neuroprotective effects in primary cultured motor neurons (Morello and Cavallaro 2015; De Paola et al. 2007).”
BackgroundResultYao, Y., Liu, F., Gu, Z., Wang, J., Xu, L., Yu, Y., Cai, J., & Ren, R. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2023.1286351 · Cited by 23 · see citing works
Lin, Y.-F., Liu, T.-T., Hu, C.-H., Chen, C.-C., & Wang, J.-Y. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.01.014 · Cited by 23 · see citing works
Morello, G., & Cavallaro, S. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.60 · Cited by 20 · see citing works
Hill, J. W., & Nemoto, E. M. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0428-z · Cited by 20 · see citing works
Yang, Y.-S., Liu, C.-Y., Pei, M.-Q., Sun, Z.-D., Lin, S., & He, H. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155987 · Cited by 19 · see citing works
Increased Il-8 Levels in the Cerebrospinal Fluid of Patients with Amyotrophic Lateral Sclerosis
Mennini, T., Giordano, L., Mengozzi, M., Ghezzi, P., Tonelli, R., Mantegazza, R., Silani, V., Corbo, M., Lunetta, C., & Beghi, E. (2009) · European Journal of Inflammation · doi:10.1177/1721727x0900700105 · Cited by 18 · see citing works
“We have recently reported that activation of CXCR2 induces dose-dependent death in cultured motor neurons (19).”
BackgroundTiwari, R. K., Moin, A., Rizvi, S. M. D., Shahid, S. M. A., & Bajpai, P. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00696-6 · Cited by 18 · see citing works
Huang, L., Xu, L., Chen, Z., Liu, Y., & Zhang, X. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11540 · Cited by 17 · see citing works
“Moreover, it has been reported that induction of CXCR1 and CXCR2 results in neuronal death and apoptosis (60,61), whereas the reduction of CXCR1 and CXCR2 attenuates inflammation and neuropathic pain (62,63).”
Cognata, V. L., Golini, E., Iemmolo, R., Balletta, S., Morello, G., Rosa, C. D., Villari, A., Marinelli, S., Vacca, V., Bonaventura, G., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105538 · Cited by 15 · see citing works
“This G-protein-coupled receptor is known for its main role of mediating neutrophils/monocytes chemotaxis and neuro-inflammatory response (De Paola et al., 2007; Won et al., 2016) through binding with at least seven C-X-C chemokines (Horuk et al., 1997; Nguyen and Stangel, 2001; Popivanova et al.,…”
BackgroundZhang, Y. L., Li, C. V., Wang, Z., Wang, T., Zhou, Y., & Zheng, L. (2023) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b22-00680 · Cited by 14 · see citing works
Oral Neuroimmune Network and Mast Cells
Karapanou, V., Kempuraj, D., & Theoharides, T. C. (2009) · European Journal of Inflammation · doi:10.1177/1721727x0900700101 · Cited by 14 · see citing works
The multifaceted role of the CXC chemokines and receptors signaling axes in ALS pathophysiology
Cognata, V. L., Morello, G., Guarnaccia, M., & Cavallaro, S. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102587 · Cited by 9 · see citing works
Ma, K., An, C., Li, M., Zhang, Y., Ren, M., Wei, Y., Xu, W., Wang, R., Bai, Y., Zhang, H., et al. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s489860 · Cited by 9 · see citing works
Cognata, V. L., D’Amico, A. G., Maugeri, G., Morello, G., Guarnaccia, M., Magrì, B., Aronica, E., D’Agata, V., & Cavallaro, S. (2023) · Cells · doi:10.3390/cells12141813 · Cited by 9 · see citing works
Aquino, G. V., Dabi, A., Odom, G., Zhang, F., & Bruce, E. D. (2021) · Toxicology · doi:10.1016/j.tox.2021.152748 · Cited by 9 · see citing works
Rodent Model of Cardiopulmonary Bypass Demonstrates Systemic Inflammation and Neuromarker Changes
Zhang, A. Y., Haywood, N. S., Money, D., Byler, M. R., Osuru, H. P., Atluri, N., Laubach, V. E., Mehaffey, J. H., Charlton, J. R., Lunardi, N., et al. (2024) · Journal of Surgical Research · doi:10.1016/j.jss.2024.09.041 · Cited by 2 · see citing works
Deftu, A. T., Deftu, A., & Ristoiu, V. (2016) · Archives of Biological Sciences · doi:10.2298/abs160513074d · Cited by 2 · see citing works
“Similar to CXCL1, it can exert diverse effects, such as stimulating axonal outgrowth [15], suppressing the growth of lung carcinoma [16], promoting neuropathic pain [17], modulating functional properties of the AMPA-type glutamate receptor GluR1 [18] or increasing apoptosis and neurodegeneration [19,20].”
BackgroundLow Molecular Weight CXCR2 Antagonists as Promising Therapeutics
Mihara, K., & Wijkmans, J. C. H. M. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527631995.ch12 · Cited by 1 · see citing works
Chemokiny i ich receptory na neuronach a proces neurodegeneracji i neuroprotekcji
Woliński, P., & Glabinski, A. R. (2011) · DOAJ (DOAJ: Directory of Open Access Journals)
- Authors
- De Paola, M., Buanne, P., Biordi, L., Bertini, R., Ghezzi, P., & Mennini, T.
- Affiliations
- University of L'Aquila (IT)
- Mario Negri Institute for Pharmacological Research (IT)
- Venue
- NeuroImmunoModulation
- Publisher
- S. Karger AG
- Published
- 2007
- Volume
- 14
- Issue
- 6
- Pages
- 310-316
- ISSN
- 1021-7401 (ISSN-L)
- 1423-0216
- OpenAlex
- W1991112774
- Cited by
- 47
- References
- 32
- Citations by year
- 2024: 4 · 2023: 4 · 2022: 2 · 2021: 5 · 2020: 2 · 2019: 1 · 2018: 5 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 1 · 2013: 4 · 2012: 1
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- NeuroImmunoModulation (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research information system (University of Urbino) (submittedVersion)
- Funders
- Ministero della Salute
- Topics
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
- Keywords
- CXCL2, CXCR2, chemokines, motor neuron degeneration, neurotoxicity, reparixin, motor neurons, interleukin-8, central nervous system disorders
- MeSH terms
- Animals, Cells, Cultured, Fluorescent Antibody Technique, Immunohistochemistry, Motor Neurons, Nerve Degeneration, Sulfonamides, Cell Death, Rats, Sprague-Dawley, Mice, Knockout, Receptors, Interleukin-8B, Mice, Rats, Chemokine CXCL2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
